152 related articles for article (PubMed ID: 38231045)
1. Real-world comparative effectiveness of palbociclib plus aromatase inhibitor in HR+/HER2- metastatic breast cancer.
Robert N; Chen C; Kim S; Zhang Z; Aguilar KM; Wang Y; Li B; Gaffney M; Huang X; McRoy L
Future Oncol; 2024 Apr; 20(12):761-780. PubMed ID: 38231045
[TBL] [Abstract][Full Text] [Related]
2. Real-World Tumor Response of Palbociclib in Combination With an Aromatase Inhibitor as First-Line Therapy in Pre/Perimenopausal Women With Metastatic Breast Cancer.
DeMichele A; Robert N; Chen C; Kim S; Zhang Z; Lu DR; Aguilar KM; Wang Y; Li B; Schneeweiss S; Rassen JA; Gaffney M; McRoy L
Target Oncol; 2023 Jul; 18(4):543-558. PubMed ID: 37428347
[TBL] [Abstract][Full Text] [Related]
3. Real-world treatment patterns for palbociclib plus an aromatase inhibitor, or an aromatase inhibitor alone, for patients with metastatic breast cancer in the Flatiron Database.
Rugo HS; Liu X; Li B; McRoy L; Chen C; Layman RM; Brufsky A
Int J Cancer; 2024 Feb; 154(4):701-711. PubMed ID: 37831416
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice.
DeMichele A; Cristofanilli M; Brufsky A; Liu X; Mardekian J; McRoy L; Layman RM; Emir B; Torres MA; Rugo HS; Finn RS
Breast Cancer Res; 2021 Mar; 23(1):37. PubMed ID: 33761995
[TBL] [Abstract][Full Text] [Related]
5. Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice.
Brufsky A; Liu X; Li B; McRoy L; Layman RM
Target Oncol; 2021 Sep; 16(5):601-611. PubMed ID: 34338965
[TBL] [Abstract][Full Text] [Related]
6. Real-World Effectiveness of Palbociclib Plus Aromatase Inhibitors in African American Patients With Metastatic Breast Cancer.
Rugo HS; Liu X; Li B; McRoy L; Chen C; Layman RM; Brufsky A
Oncologist; 2023 Oct; 28(10):866-874. PubMed ID: 37487056
[TBL] [Abstract][Full Text] [Related]
7. Real-World Treatment Patterns and Outcomes of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer: Flatiron Database Analysis.
Patt D; Liu X; Li B; McRoy L; Layman RM; Brufsky A
Clin Breast Cancer; 2022 Aug; 22(6):601-610. PubMed ID: 35643624
[TBL] [Abstract][Full Text] [Related]
8. P-REALITY X: A Real-World Analysis of Palbociclib Plus an Aromatase Inhibitor in HR+/HER2- Metastatic Breast Cancer-A Podcast.
Brufsky A; Gallagher C
Target Oncol; 2023 May; 18(3):321-326. PubMed ID: 37148492
[TBL] [Abstract][Full Text] [Related]
9. Real-world treatment of patients with palbociclib for HR+/HER2-advanced/metastatic breast cancer: the Europe IRIS study.
Mycock K; Zhan L; Hart K; Taylor-Stokes G; Milligan G; Atkinson C; Mitra D
Future Oncol; 2022 Jan; 18(3):349-362. PubMed ID: 34842454
[TBL] [Abstract][Full Text] [Related]
10. Real-world treatment patterns and effectiveness of palbociclib plus an aromatase inhibitor in patients with metastatic breast cancer aged 75 years or older.
Brufsky A; Liu X; Li B; McRoy L; Chen C; Layman RM; Rugo HS
Front Oncol; 2023; 13():1237751. PubMed ID: 37841423
[TBL] [Abstract][Full Text] [Related]
11. Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+/HER2-negative advanced/metastatic breast cancer in real-world settings in the US: Results from the IRIS study.
Taylor-Stokes G; Mitra D; Waller J; Gibson K; Milligan G; Iyer S
Breast; 2019 Feb; 43():22-27. PubMed ID: 30391832
[TBL] [Abstract][Full Text] [Related]
12. Real-World Treatment Patterns and Clinical Effectiveness of Palbociclib Plus an Aromatase Inhibitor as First-Line Therapy in Advanced/Metastatic Breast Cancer: Analysis from the US Syapse Learning Health Network.
Law JW; Mitra D; Kaplan HG; Alfred T; Brufsky AM; Emir B; McCracken H; Liu X; Broome RG; Zhang C; DiCristo C; Chen C
Curr Oncol; 2022 Feb; 29(2):1047-1061. PubMed ID: 35200588
[TBL] [Abstract][Full Text] [Related]
13. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Finn RS; Crown JP; Lang I; Boer K; Bondarenko IM; Kulyk SO; Ettl J; Patel R; Pinter T; Schmidt M; Shparyk Y; Thummala AR; Voytko NL; Fowst C; Huang X; Kim ST; Randolph S; Slamon DJ
Lancet Oncol; 2015 Jan; 16(1):25-35. PubMed ID: 25524798
[TBL] [Abstract][Full Text] [Related]
14. Real-world treatment patterns and clinical outcomes in patients receiving palbociclib combinations for HR+/HER2- advanced/metastatic breast cancer in Japan: Results from the IRIS study.
Mycock K; Zhan L; Hart K; Taylor-Stokes G; Milligan G; Atkinson C; Mitra D
Cancer Treat Res Commun; 2022; 32():100573. PubMed ID: 35567914
[TBL] [Abstract][Full Text] [Related]
15. Progression-Free Survival for Real-World Use of Palbociclib in Hormone Receptor-Positive Metastatic Breast Cancer.
Wilkie J; Schickli MA; Berger MJ; Lustberg M; Reinbolt R; Noonan A; Ramaswamy B; Sardesai S; VanDeusen J; Wesolowski R; Williams N; Stover DG; Li J; Vargo CA
Clin Breast Cancer; 2020 Feb; 20(1):33-40. PubMed ID: 31451366
[TBL] [Abstract][Full Text] [Related]
16. Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2- metastatic breast cancer patients compared to endocrine therapy alone in the second-line setting: A large institutional study.
Ha MJ; Singareeka Raghavendra A; Kettner NM; Qiao W; Damodaran S; Layman RM; Hunt KK; Shen Y; Tripathy D; Keyomarsi K
Int J Cancer; 2022 Jun; 150(12):2025-2037. PubMed ID: 35133007
[TBL] [Abstract][Full Text] [Related]
17. Prolonging the lives of African-Americans with metastatic breast cancer by adding palbociclib to an aromatase inhibitor in routine clinical practice: a plain language summary of a real-world database study.
Rugo HS; Liu X; Li B; McRoy L; Chen C; Layman RM; Tomlin-Harris T; Brufsky A
Future Oncol; 2024 Mar; ():1-9. PubMed ID: 38517416
[TBL] [Abstract][Full Text] [Related]
18. Real-world effectiveness and sensitivity of palbociclib plus endocrine therapy in HR+/HER2- patients with metastatic breast cancer.
Li J; Zhang X; Yang C; Lv Y; Yang H; Kong X; Han M; Wang Z; Ma J; Han J; Liu Y
Medicine (Baltimore); 2021 Nov; 100(44):e27710. PubMed ID: 34871262
[TBL] [Abstract][Full Text] [Related]
19. Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer in Argentina: The IRIS Study.
Waller J; Mitra D; Mycock K; Taylor-Stokes G; Milligan G; Zhan L; Iyer S
J Glob Oncol; 2019 May; 5():JGO1800239. PubMed ID: 31050919
[TBL] [Abstract][Full Text] [Related]
20. Real-World Effectiveness of Palbociclib Plus Letrozole vs Letrozole Alone for Metastatic Breast Cancer With Lung or Liver Metastases: Flatiron Database Analysis.
Brufsky A; Liu X; Li B; McRoy L; Layman RM
Front Oncol; 2022; 12():865292. PubMed ID: 35860587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
